Grace Colon is the founder of InCarda Therapeutics. InCarda Therapeutics has raised $120M in total funding. Latest round: Series C. Backed by Innoviva.
Grace E. Colón, Ph.D., is a biotechnology CEO and board member. She previously served as CEO of InCarda Therapeutics, where she raised over $120M and advanced their lead product for paroxysmal atrial fibrillation from preclinical to Phase 3. She is currently the co-founder and CEO of Inaya Therapeutics.
Full founder directory · Investor directory · Company funding database · Fundraising library